

# Sylvia K Plevritis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8520323/publications.pdf>

Version: 2024-02-01

116  
papers

16,211  
citations

46984

47  
h-index

25770

108  
g-index

118  
all docs

118  
docs citations

118  
times ranked

24972  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiomics Analysis of Spatially Distinct Stromal Cells Reveals Tumor-Induced O-Glycosylation of the CDK4/pRB Axis in Fibroblasts at the Invasive Tumor Edge. <i>Cancer Research</i> , 2022, 82, 648-664.	0.4	9
2	Reconstructing codependent cellular cross-talk in lung adenocarcinoma using REMI. <i>Science Advances</i> , 2022, 8, eabi4757.	4.7	6
3	Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. <i>Cell</i> , 2022, 185, 1924-1942.e23.	13.5	111
4	Identification of cell types in multiplexed in situ images by combining protein expression and spatial information using CELESTA. <i>Nature Methods</i> , 2022, 19, 759-769.	9.0	42
5	Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 988.	3.8	181
6	Reflecting on 20 years of breast cancer modeling in CISNET: Recommendations for future cancer systems modeling efforts. <i>PLoS Computational Biology</i> , 2021, 17, e1009020.	1.5	9
7	A risk-based framework for assessing real-time lung cancer screening eligibility that incorporates life expectancy and past screening findings. <i>Cancer</i> , 2021, 127, 4432-4446.	2.0	7
8	Evaluation of Alternative Diagnostic Follow-up Intervals for Lung Reporting and Data System Criteria on the Effectiveness of Lung Cancer Screening. <i>Journal of the American College of Radiology</i> , 2021, 18, 1614-1623.	0.9	2
9	A Cost-Effectiveness Analysis of Lung Cancer Screening With Low-Dose Computed Tomography and a Diagnostic Biomarker. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab081.	1.4	10
10	Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening. <i>JAMA Oncology</i> , 2021, 7, 1833.	3.4	29
11	A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies. <i>Journal of the National Cancer Institute</i> , 2020, 112, 466-479.	3.0	67
12	Cost-Effectiveness Analysis of Lung Cancer Screening in the United States. <i>Annals of Internal Medicine</i> , 2020, 172, 706-707.	2.0	2
13	Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line. <i>Nature Communications</i> , 2020, 11, 2345.	5.8	74
14	Risk-Based lung cancer screening: A systematic review. <i>Lung Cancer</i> , 2020, 147, 154-186.	0.9	136
15	Disparities of National Lung Cancer Screening Guidelines in the US Population. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1136-1142.	3.0	48
16	Cost-Effectiveness Analysis of Lung Cancer Screening Accounting for the Effect of Indeterminate Findings. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz035.	1.4	22
17	Sparse discriminative latent characteristics for predicting cancer drug sensitivity from genomic features. <i>PLoS Computational Biology</i> , 2019, 15, e1006743.	1.5	4
18	Cost-Effectiveness Analysis of Lung Cancer Screening in the United States. <i>Annals of Internal Medicine</i> , 2019, 171, 796.	2.0	81

#	ARTICLE	IF	CITATIONS
19	Precision Medicine in Pancreatic Disease—Knowledge Gaps and Research Opportunities. <i>Pancreas</i> , 2019, 48, 1250-1258.	0.5	9
20	TRAIL-induced variation of cell signaling states provides nonheritable resistance to apoptosis. <i>Life Science Alliance</i> , 2019, 2, e201900554.	1.3	11
21	DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E4294-E4303.	3.3	42
22	Distinguishing between CISNET model results versus CISNET models. <i>Cancer</i> , 2018, 124, 1083-1084.	2.0	0
23	Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 154.	3.8	209
24	Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling. <i>Medical Decision Making</i> , 2018, 38, 9S-23S.	1.2	37
25	Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models. <i>Medical Decision Making</i> , 2018, 38, 3S-8S.	1.2	31
26	A Molecular Subtype—Specific Stochastic Simulation Model of US Breast Cancer Incidence, Survival, and Mortality Trends from 1975 to 2010. <i>Medical Decision Making</i> , 2018, 38, 89S-98S.	1.2	8
27	Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment. <i>Medical Decision Making</i> , 2018, 38, 32S-43S.	1.2	26
28	Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49. <i>Medical Decision Making</i> , 2018, 38, 140S-150S.	1.2	13
29	Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology. <i>Medical Decision Making</i> , 2018, 38, 112S-125S.	1.2	11
30	Non—Small Cell Lung Cancer Radiogenomics Map Identifies Relationships between Molecular and Imaging Phenotypes with Prognostic Implications. <i>Radiology</i> , 2018, 286, 307-315.	3.6	140
31	Re: Think before you leap. <i>International Journal of Cancer</i> , 2018, 142, 1507-1509.	2.3	0
32	A radiogenomic dataset of non-small cell lung cancer. <i>Scientific Data</i> , 2018, 5, 180202.	2.4	167
33	Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky062.	1.4	199
34	Caution Needed for Analyzing the Risks of Second Cancers. <i>Journal of Thoracic Oncology</i> , 2018, 13, e172-e173.	0.5	1
35	<i>GFPT2</i> -Expressing Cancer-Associated Fibroblasts Mediate Metabolic Reprogramming in Human Lung Adenocarcinoma. <i>Cancer Research</i> , 2018, 78, 3445-3457.	0.4	75
36	Contributions of Screening and Treatment to Mortality From Breast Cancer—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2336.	3.8	1

#	ARTICLE	IF	CITATIONS
37	The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. <i>International Journal of Cancer</i> , 2017, 140, 2436-2443.	2.3	36
38	Predictive radiogenomics modeling of EGFR mutation status in lung cancer. <i>Scientific Reports</i> , 2017, 7, 41674.	1.6	124
39	Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model. <i>Cancer Causes and Control</i> , 2017, 28, 947-958.	0.8	38
40	Intestinal Enteroendocrine Lineage Cells Possess Homeostatic and Injury-Inducible Stem Cell Activity. <i>Cell Stem Cell</i> , 2017, 21, 78-90.e6.	5.2	280
41	Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. <i>PLoS Medicine</i> , 2017, 14, e1002277.	3.9	216
42	Risk Stratification for Second Primary Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2893-2899.	0.8	92
43	Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative 18F FDG-PET/CT metrics. <i>Oncotarget</i> , 2017, 8, 52792-52801.	0.8	32
44	PS01.77: Risk-Stratification for Second Primary Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, S319-S320.	0.5	2
45	Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. <i>Annals of Internal Medicine</i> , 2016, 164, 215.	2.0	209
46	Visualization and cellular hierarchy inference of single-cell data using SPADE. <i>Nature Protocols</i> , 2016, 11, 1264-1279.	5.5	99
47	Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1116-25.	3.3	307
48	The prognostic landscape of genes and infiltrating immune cells across human cancers. <i>Nature Medicine</i> , 2015, 21, 938-945.	15.2	2,505
49	Pancancer analysis of DNA methylation-driven genes using MethylMix. <i>Genome Biology</i> , 2015, 16, 17.	3.8	117
50	Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv211.	3.0	64
51	ARF: Connecting senescence and innate immunity for clearance. <i>Aging</i> , 2015, 7, 613-615.	1.4	3
52	p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia. <i>Oncotarget</i> , 2015, 6, 3563-3577.	0.8	20
53	Abstract A48: Gene expression signatures associated with MYC oncogene addiction in lymphoma. , 2015, , .		0
54	Comparing Benefits from Many Possible Computed Tomography Lung Cancer Screening Programs: Extrapolating from the National Lung Screening Trial Using Comparative Modeling. <i>PLoS ONE</i> , 2014, 9, e99978.	1.1	38

#	ARTICLE	IF	CITATIONS
55	CCAST: A Model-Based Gating Strategy to Isolate Homogeneous Subpopulations in a Heterogeneous Population of Single Cells. <i>PLoS Computational Biology</i> , 2014, 10, e1003664.	1.5	26
56	Bridging Population and Tissue Scale Tumor Dynamics: A New Paradigm for Understanding Differences in Tumor Growth and Metastatic Disease. <i>Cancer Research</i> , 2014, 74, 426-435.	0.4	18
57	Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. <i>Cancer</i> , 2014, 120, 1713-1724.	2.0	65
58	NF- $\kappa$ B protein expression associates with 18F-FDG PET tumor uptake in non-small cell lung cancer: A radiogenomics validation study to understand tumor metabolism. <i>Lung Cancer</i> , 2014, 83, 189-196.	0.9	51
59	Effects of Screening and Systemic Adjuvant Therapy on ER-Specific US Breast Cancer Mortality. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	120
60	Glioblastoma Multiforme: Exploratory Radiogenomic Analysis by Using Quantitative Image Features. <i>Radiology</i> , 2014, 273, 168-174.	3.6	265
61	Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. <i>Nature Medicine</i> , 2014, 20, 769-777.	15.2	349
62	Raising the Bar for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2014, 161, 532.	2.0	2
63	Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2014, 160, 311.	2.0	377
64	TreeVis: A MATLAB-based tool for tree visualization. <i>Computer Methods and Programs in Biomedicine</i> , 2013, 109, 74-76.	2.6	6
65	Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers. <i>Familial Cancer</i> , 2013, 12, 65-73.	0.9	11
66	Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. <i>Blood</i> , 2013, 121, 1604-1611.	0.6	279
67	Identification of ovarian cancer driver genes by using module network integration of multi-omics data. <i>Interface Focus</i> , 2013, 3, 20130013.	1.5	50
68	Cross-Species Functional Analysis of Cancer-Associated Fibroblasts Identifies a Critical Role for CLCF1 and IL-6 in Non-“Small Cell Lung Cancer <i>In Vivo</i> ”. <i>Cancer Research</i> , 2012, 72, 5744-5756.	0.4	96
69	A Simulation Model to Predict the Impact of Prophylactic Surgery and Screening on the Life Expectancy of <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1066-1077.	1.1	43
70	Online Tool to Guide Decisions for <i>BRCA1/2</i> Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2012, 30, 497-506.	0.8	81
71	Prognostic PET 18F-FDG Uptake Imaging Features Are Associated with Major Oncogenomic Alterations in Patients with Resected Non-“Small Cell Lung Cancer. <i>Cancer Research</i> , 2012, 72, 3725-3734.	0.4	111
72	Non-“Small Cell Lung Cancer: Identifying Prognostic Imaging Biomarkers by Leveraging Public Gene Expression Microarray Data” Methods and Preliminary Results. <i>Radiology</i> , 2012, 264, 387-396.	3.6	384

#	ARTICLE	IF	CITATIONS
73	Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1071-1081.	1.9	6
74	Comparing the benefits of screening for breast cancer and lung cancer using a novel natural history model. <i>Cancer Causes and Control</i> , 2012, 23, 175-185.	0.8	21
75	Systematic Deconvolution of Hematolymphoid Tumor Transcriptomes Reveals Infiltrating Immune Cell Signatures Related to Survival.. <i>Blood</i> , 2012, 120, 2390-2390.	0.6	3
76	Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. <i>Nature Biotechnology</i> , 2011, 29, 886-891.	9.4	905
77	Reconstructing Directed Signed Gene Regulatory Network From Microarray Data. <i>IEEE Transactions on Biomedical Engineering</i> , 2011, 58, 3518-3521.	2.5	9
78	Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum. <i>Science</i> , 2011, 332, 687-696.	6.0	2,097
79	Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 17432-17437.	3.3	38
80	Discovering Biological Progression Underlying Microarray Samples. <i>PLoS Computational Biology</i> , 2011, 7, e1001123.	1.5	42
81	Identification of LMO2 Transcriptome and Interactome in Diffuse Large B-Cell Lymphoma by Integrated Experimental and Computational Approach. <i>Blood</i> , 2011, 118, 438-438.	0.6	0
82	Survival Analysis of Cancer Risk Reduction Strategies for <i>BRCA1/2</i> Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2010, 28, 222-231.	0.8	217
83	A Simulation Model Investigating the Impact of Tumor Volume Doubling Time and Mammographic Tumor Detectability on Screening Outcomes in Women Aged 40-49 Years. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1263-1271.	3.0	37
84	Reducing the Computational Complexity of Information Theoretic Approaches for Reconstructing Gene Regulatory Networks. <i>Journal of Computational Biology</i> , 2010, 17, 169-176.	0.8	6
85	Incidental Extracardiac Findings at Coronary CT: Clinical and Economic Impact. <i>American Journal of Roentgenology</i> , 2010, 194, 1531-1538.	1.0	73
86	Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2706.	3.8	339
87	MiDReG: A method of mining developmentally regulated genes using Boolean implications. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 5732-5737.	3.3	57
88	Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment. <i>Blood</i> , 2010, 116, 2006-2006.	0.6	0
89	A Bayesian nonparametric method for model evaluation: application to genetic studies. <i>Journal of Nonparametric Statistics</i> , 2009, 21, 379-396.	0.4	2
90	Ly6d marks the earliest stage of B-cell specification and identifies the branchpoint between B-cell and T-cell development. <i>Genes and Development</i> , 2009, 23, 2376-2381.	2.7	254

#	ARTICLE	IF	CITATIONS
91	Simultaneous Class Discovery and Classification of Microarray Data Using Spectral Analysis. Journal of Computational Biology, 2009, 16, 935-944.	0.8	10
92	Fast calculation of pairwise mutual information for gene regulatory network reconstruction. Computer Methods and Programs in Biomedicine, 2009, 94, 177-180.	2.6	52
93	Modeling the transition of lung cancer from early to advanced stage. Cancer Causes and Control, 2009, 20, 1559-1569.	0.8	6
94	Effects of Mammography Screening Under Different Screening Schedules: Model Estimates of Potential Benefits and Harms. Annals of Internal Medicine, 2009, 151, 738.	2.0	509
95	Gene Expression Signature of Host Immune Response Is Predictive of Follicular Lymphoma Patient Survival in Independent Cohorts, and Correlates with Transformation to Diffuse Large B-Cell Lymphoma.. Blood, 2009, 114, 2951-2951.	0.6	0
96	Genomic and Proteomic Analysis Reveals a Threshold Level of MYC Required for Tumor Maintenance. Cancer Research, 2008, 68, 5132-5142.	0.4	87
97	Extracting binary signals from microarray time-course data. Nucleic Acids Research, 2007, 35, 3705-3712.	6.5	145
98	A natural history model of stage progression applied to breast cancer. Statistics in Medicine, 2007, 26, 581-595.	0.8	54
99	Ductal Pattern Enhancement on Magnetic Resonance Imaging of the Breast Due to Ductal Lavage. Breast Journal, 2007, 13, 281-286.	0.4	5
100	Effect of Screening and Adjuvant Therapy on Mortality From Breast Cancer. Obstetrical and Gynecological Survey, 2006, 61, 179-180.	0.2	44
101	Cost-effectiveness of Screening BRCA1/2 Mutation Carriers With Breast Magnetic Resonance Imaging. JAMA - Journal of the American Medical Association, 2006, 295, 2374.	3.8	240
102	Chapter 12: A Stochastic Simulation Model of U.S. Breast Cancer Mortality Trends From 1975 to 2000. Journal of the National Cancer Institute Monographs, 2006, 2006, 86-95.	0.9	45
103	Magnetic Resonance Imaging Characteristics of Fibrocystic Change of the Breast. Investigative Radiology, 2005, 40, 436-441.	3.5	38
104	Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. Health Expectations, 2005, 8, 221-233.	1.1	18
105	The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER database. Breast Cancer Research and Treatment, 2005, 89, 47-54.	1.1	118
106	Decision Analysis and Simulation Modeling for Evaluating Diagnostic Tests on the Basis of Patient Outcomes. American Journal of Roentgenology, 2005, 185, 581-590.	1.0	16
107	Ductal Lavage of Fluid-Yielding and Non-Fluid-Yielding Ducts in BRCA1 and BRCA2 Mutation Carriers and Other Women at High Inherited Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1082-1089.	1.1	27
108	Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer. New England Journal of Medicine, 2005, 353, 1784-1792.	13.9	2,169

#	ARTICLE	IF	CITATIONS
109	Simulation-based parameter estimation for complex models: a breast cancer natural history modelling illustration. <i>Statistical Methods in Medical Research</i> , 2004, 13, 507-524.	0.7	17
110	Diversity of model approaches for breast cancer screening: a review of model assumptions by The Cancer Intervention and Surveillance Network (CISNET) Breast Cancer Groups. <i>Statistical Methods in Medical Research</i> , 2004, 13, 525-538.	0.7	20
111	Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. <i>Cancer</i> , 2004, 100, 479-489.	2.0	77
112	Ethical Issues in Contrast-Enhanced Magnetic Resonance Imaging Screening for Breast Cancer. <i>Topics in Magnetic Resonance Imaging</i> , 2002, 13, 79-84.	0.7	9
113	A mathematical algorithm that computes breast cancer sizes and doubling times detected by screening. <i>Mathematical Biosciences</i> , 2001, 171, 155-178.	0.9	14
114	Digital Storage Phosphor Chest Radiography: An ROC Study of the Effect of 2K versus 4K Matrix Size on Observer Performance. <i>Radiology</i> , 2001, 218, 527-532.	3.6	16
115	Cost-Effectiveness Analysis of New Image-Based Screening Technologies. <i>Computer Aided Surgery</i> , 2000, 5, 134-134.	1.8	0
116	MRS imaging using anatomically based K-space sampling and extrapolation. <i>Magnetic Resonance in Medicine</i> , 1995, 34, 686-693.	1.9	33